OR WAIT 15 SECS
© 2020 MJH Life Sciences and Pharmaceutical Executive. All rights reserved.
© 2020 MJH Life Sciences™ and Pharmaceutical Executive. All rights reserved.
June 01, 2011
Emerging Pharma Leaders 2011
FDA's opiod REMS implies there is still value in industry-sponsored CME
The payoff is superior performance in key areas such as clinical trials
Carefully crafting your brand's positioning could ensure that you'll not just win the sprint, but also the marathon
With Yankee stadium as the backdrop, Pharm Exec convened its annual panel of eight business development experts to crack the bat on best practice in licensing and M&A for the year ahead.
NicVAX is trying to buck the trend of smoking-cessation products' high failure rate
Pharma company communicators must steer the conversation about vaccines to the ultimate goal-preventing disease
Why has the EU still not managed to update its rules on information about medicines?
Part II of The Avoca Group's 2011 CRO survey on clinical development outsourcing relationships
NeHC's new Consumer Consortium is promoting a new stakeholder agenda to improve patient knowledge
Meet 2011's Emerging Pharma Leaders-Can these 30 trendsetters build competitive scale from scarcity?
Creating and managing expectations is the most basic rule of marketing
Successful negotiations require a willingness to take risks and an ability to adapt
Patent expiries are inevitable, but brand teams should look to graduate the sales curve
What do our genetics tell us about our predisposition to certain diseases?
A vaccination against addiction could open up a whole new category
To decide on a course of treatment, patients need to be told the truth straight up
Now that government payers are turning to pharma to bridge budgetary shortfalls it's best to think long-term
The three components of the NicVAX launch challenge
With a first-in-class compound marketers can potentially leverage long-lasting market advantages
Suggestions for testing new ways of addressing difficult issues of risk